OARS funding Biomed

This Funding Opportunity Announcement (FOA) invites applications for basic research to elucidate the impact of microenvironment, which includes cellular components of the niche, extracellular matrix, and soluble factors, on lung progenitor cell phenotype and function during development, homeostasis, repair and regeneration. Multi-disciplinary teams with complementary expertise are encouraged to propose innovative, hypothesis-based studies to catalyze this understudied area critical to advancing lung stem cell biology. This FOA will also support the development of novel 3-dimensional, multi-component models to interrogate lung stem cell niches.

This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Research Resources (BTRR). These Resources conduct research and development of new or improved technologies driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Resources technologies and experimental results. Resources should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. New applicants are strongly encouraged to submit a pre-application in response to PAR-17-315 The pre-application process provides feedback on whether the proposed technology development is appropriate for the NIGMS BTRR program, and the potential competitiveness of a full application.

This Funding Opportunity Announcement (FOA) will support small grants on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research. The R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Investigators who have not received independent NIH funding or independent NIH funding in this field are encouraged to apply to this FOA

This Funding Opportunity Announcement (FOA) will support innovative exploratory/developmental investigations on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research.

CurePSP, a nonprofit research and grantmaking organization, works to increase awareness of progressive supranuclear palsy, corticobasal degeneration, and other atypical Parkinsonian disorders; fund research toward treatment, cure and prevention; educate healthcare professionals; and provide support, information, and hope for affected persons and their families. To that end, the organization is accepting applications for student fellowships for research on progressive supranuclear palsy.

The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the impact of substance abuse on HIV, HIV/HCV co-infection associated disease progression, (b) the pathogenic interactions between HIV and hepatitis C virus, (c) hepatic and non-hepatic co-morbidities associated with HIV/HCV-co-infections in people with substance abuse disorders (SUDs), and (d) the effectiveness of interferon-free direct acting antiviral (DAAs) drug regimens to treat HIV/HCV co-infections in people with SUDs

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. The present announcement seeks R01 applications. ALSO listed (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the impact of substance abuse on HIV, HIV/HCV co-infection associated disease progression, (b) the pathogenic interactions between HIV and hepatitis C virus, (c) hepatic and non-hepatic co-morbidities associated with HIV/HCV-co-infections in people with substance abuse disorders (SUDs), and (d) the effectiveness of interferon-free direct acting antiviral (DAAs) drug regimens to treat HIV/HCV co-infections in people with SUDs. This FOA is informed by priority area in the NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html and the HHS National Viral Hepatitis Action Plan 2017-2020: https://www.hhs.gov/hepatitis/blog/2017/01/19/updated-national-viral-hepatitis-action-plan-2017-2020.html

The Office of Naval Research (ONR) is interested in receiving proposals for its Young Investigator Program (YIP). ONR's Young Investigator Program (YIP) seeks to identify and support academic scientists and engineers who are in their first or second full-time tenure-track or tenure-track-equivalent academic appointment, have begun their first appointment on or after 31 December 2012, and who show exceptional promise for doing creative research. The objectives of this program are to attract outstanding faculty members of Institutions of Higher Education (hereafter also called "universities") to the Department of the Navy's Science and Technology (S&T) research program, to support their research, and to encourage their teaching and research careers. Proposals addressing research areas (as described in the ONR Science and Technology Department section of ONR's website at www.onr.navy.mil) which are of interest to ONR program officers will be considered. Contact information for each division (a subgroup of an S&T Department) is also listed within the S&T section of the website

The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory basic research to develop innovative phylodynamic approaches to identify and prioritize the most rapidly growing HIV transmission clusters within a given population of individuals in near-real time. 

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of imaging approaches to identify and characterize persistent HIV reservoirs in patients undergoing suppressive antiretroviral therapy (ART) and to quantify the nature and size of these reservoirs in response to therapeutic interventions.

The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory basic research to develop innovative phylodynamic approaches to identify and prioritize the most rapidly growing HIV transmission clusters within a given population of individuals in near-real time.

NIST is soliciting applications from eligible institutions of higher education in the U.S. and its territories that offer two- or four- year degrees in academic science, technology, engineering and mathematics (STEM) disciplines, which include but are not limited to biochemistry, biological sciences, chemistry, computer science, engineering, electronics, materials science, mathematics, nanoscale science, neutron science, physical sciences, physics, and statistics, to establish and manage a program to support collaborative research relationships among NIST staff, undergraduate and graduate students, individuals with bachelor's or master's degrees, post-doctoral fellows, and academic affiliates, and the PREP researchers' academic institutions. These collaborative relationships will include research opportunities at the relevant NIST campuses in Boulder, Colorado (CO) (PREP Boulder), or Gaithersburg, Maryland (MD), and/or Charleston, South Carolina (SC) (PREP Gaithersburg). Eligible applicants may apply to establish and manage a PREP Boulder program or a PREP Gaithersburg program or may apply to establish and manage programs for both.

The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.

The Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) is organized into five Joint Project Management Offices (JPMO), each responsible for specific commodity areas. General information on the JPEO-CBD and subordinate JPMOs can be obtained from the JPEO-CBD website at http://www.jpeocbd.osd.mil/. The medical CBRN countermeasures developed by the Joint Project Manager Medical Countermeasure Systems (JPM MCS) office directly support the current, near-term, and far-term challenges by providing the capability to prevent, diagnose and treat the effects of chemical, radiological and biological warfare agents. Mission areas and technical points of contact for the product management offices within the JPM MCS are shown in Section VII of this BAA. Proposals are sought from all eligible sources as specified herein, including educational institutions, nonprofit organizations, and private industry. This Broad Agency Announcement (BAA) provides general information, proposal preparation instructions, evaluation and selection criteria, and award administration.

The Alzheimer's Drug Discovery Foundation, in partnership with the Association for Frontotemporal Degeneration, has issued a Request for Proposals designed to accelerate and support innovative drug discovery programs for FTD, a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain.

The Histiocytosis Association is a global nonprofit organization dedicated to addressing the unique needs of patients and families dealing with the effects of histiocytic disorders, a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can lead to organ damage and tumor formation in both children and adults. The only organization of its kind, HA works to encourage the patient and medical communities to improve and share knowledge of histiocytic disorders; provide critical emotional and educational support to patients and families; and identify and fund key research initiatives that lead to a world free of histiocytic disorders.

The Desmoid Tumor Research Foundation is the only foundation in the world dedicated to facilitating and funding research for a cure for desmoid tumors. The foundation funds research that uses cutting-edge science and creative clinical applications, as well as novel approaches that address potential leads based on prior research.

The Histiocytosis Association is a global nonprofit organization dedicated to addressing the unique needs of patients and families dealing with the effects of histiocytic disorders, a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can lead to organ damage and tumor formation in both children and adults. The only organization of its kind, HA works to encourage the patient and medical communities to improve and share knowledge of histiocytic disorders; provide critical emotional and educational support to patients and families; and identify and fund key research initiatives that lead to a world free of histiocytic disorders.